Русский
Cost of medicamentous therapy and clinical characteristics of patients with late stage rheumatoid arthritis and arterial hypertension
DOI: https://dx.doi.org/10.18565/therapy.2024.7.74-80
Chulkov V.S., Okonenko T.I., Khrutsky A.K., Zhmaylova S.V.
Yaroslav-the-Wise Novgorod State University, Veliky Novgorod
The aim: to give clinical characteristic and calculate the cost of medicamentous therapy in late-stage RA patients having arterial hypertension.
Material and methods. 41 case history of patients with late stage RA and arterial hypertension was studied. The diagnosis of RA was based on 2010 ACR/EULAR criteria. Average hospital day was 10.2 ± 0.37 days. In the frames of the study, the clinical characteristic of this patient group was given, an analysis of used drugs was carried out, and the cost of medicamentous therapy was calculated. Information about the cost of medicines was received by us in 2022 from invoices from the supplier in day hospital.
Results. In 88.89% of cases of patients with RA it was revealed from 3 to 5 comorbid diseases. All patients were diagnosed with arterial hypertension. Doctors prescribed tsDMARDs as basic therapy; 16 drugs were used in various regimens during treatment. The total cost of a course of therapy per 100 persons was 19,937.31 rubles, with 10.7% of the costs falling on drugs for the control of arterial hypertension.
Conclusion. Of the 16 drugs used in the treatment of late-stage RA patients with arterial hypertension, all, with the exception of nicotinic acid, are included in the list of vital and essential drugs. Estimation of the cost of modern medicamentous therapy for RA with hypertension is a necessary step to optimize the costs of RA treatment in the context of the high use of hospital-substituting technologies in the treatment of patients.
Literature
1. Bogale Z., Feleke Y. Prevalence, clinical manifestations, and treatment pattern of patients with rheumatoid arthritis attending the rheumatology clinic at Tikur Anbessa specialized hospital, Ethiopia: A cross-sectional study. Open Access Rheumatol. 2022; 14: 221–29. https://doi.org/10.2147/OARRR.S383778. PMID: 36276407. PMCID: PMC9581569. 2. Aletaha D., Smolen J.S. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018; 320(13): 1360–72. https://doi.org/10.1001/jama.2018.13103. PMID: 30285183. 3. Лила А.М., Олюнин Ю.А., Гордеев А.В. Оценка статуса больных ревматоидным артритом. Современные тенденции. Современная ревматология. 2020; 14(2): 7–13. (Lila A.M., Olyunin Yu.A., Gordeev A.V. Assessing the status of patients with rheumatoid arthritis: Modern tendencies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020; 14(2): 7–13 (In Russ.)). https://doi.org/10.14412/1996-7012-2020-2-7-13. EDN: XOHCDO. 4. Насонов Е.Л., Лила А.М. Ревматоидный артрит: достижения и нерешенные проблемы. Терапевтический архив. 2019; 91(5): 4–7. (Nasonov E.L., Lila A.M. Rheumatoid arthritis: Achievements and unresolved issues. Terapevticheskiy arhiv = Therapeutic Archive. 2019; 91(5): 4–7 (In Russ.)). https://doi.org/10.26442/00403660.2019.05.000259. EDN: CCMENG. 5. Hresko A., Lin T.C., Solomon D.H. Medical care costs associated with rheumatoid arthritis in the US: A systematic literature review and meta-analysis. Arthritis care res. (Hoboken). 2018; 70(10): 1431–38. https://doi.org/10.1002/acr.23512. PMID: 29316377. PMCID: PMC6033682. 6. Tatangelo M., Tomlinson G., Paterson J.M. et al. Health care costs of rheumatoid arthritis: A longitudinal population study. PloS one. 2021; 16(5): e0251334. https://doi.org/10.1371/journal.pone.0251334. PMID: 33956894. PMCID: PMC8101709. 7. Куликов А.Ю., Серпик В.Г., Лила А.М. Фармакоэкономическое обоснование переключения пациентов с ревматическими заболеваниями с оригинальных генно-инженерных биологических препаратов на биосимиляры в условиях системы здравоохранения России. Современная ревматология. 2022; 16(2S): 1–17. (Kulikov A.Yu., Serpik V.G., Lila A.M. Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022; 16(2S): 1–17 (In Russ.)). https://doi.org/ 10.14412/1996-7012-2022-2S-1-17. 8. Моисеев С.В., Новиков П.И., Чеботарева Н.В. с соавт. Олокизумаб в лечении ревматоидного артрита. Клиническая фармакология и терапия. 2021; 30(2): 67–74. (Moiseev S.V., Novikov P.I., Chebotareva N.V. et al. Olokizumab for treatment of rheumatoid arthritis. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2021; 30(2): 67–74 (In Russ.)). https://doi.org.10.32756/0869-5490-2021-2-67-74. EDN: XSEAZY. 9. Клинические рекомендации. Ревматоидный артрит. Ассоциация ревматологов России, ОООИ «Российская ревматологическая ассоциация «Надежда». Рубрикатор клинических рекомендаций Минздрава России. 2021. Доступ: https://cr.minzdrav.gov.ru/schema/250_2 (дата обращения – 30.08.2024). (Clinical guidelines. Rheumatoid arthritis. Association of Rheumatologists of Russia, Russian Rheumatological Association “Nadezhda”. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2021. URL: https://cr.minzdrav.gov.ru/schema/250_2 (date of access – 30.08.2024) (In Russ.)). 10. Башкова И.Б., Мадянов И.В. Принципы рациональной глюкокортикоидной терапии при лечении ревматических заболеваний. Лечащий врач. 2019; (4): 24–27. (Bashkova I.B., Madyanov I.V. Approaches to rational glucocorticoid therapy in the treatment of rheumatic diseases. Lechashchiy vrach = Attending Physician. 2019; (4): 24–27 (In Russ.)). EDN: IXKGPE. 11. Каратеев А.Е. Анальгетическая терапия и проблема коморбидности. Современная ревматология. 2019; 13(3): 116–125. (Karateev A.E. Analgesic therapy and a problem of comorbidity. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019; 13(3): 116–125 (In Russ.)). https://doi.org/10/14412/1996-7012-2019-3-116-125. EDN: XZKTHW. 12. Никитина Н.М., Романова Т.А., Афанасьев И.А. с соавт. Артериальная гипертензия у больных ревматоидным артритом. Что нужно знать для диагностики и учитывать при лечении? Рациональная фармакотерапия в кардиологии. 2016; 12(5): 547–552. (Nikitina N.M., Romanova T.A., Afanasiev I.A. et al. Arterial hypertension in patients with rheumatoid arthritis. what should be known and considered at diagnosis and treatment? Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2016; 12(5): 547–552 (In Russ.)). https://doi.org/10.20996/1819-6446-2016-12-5-547-55. EDN: WYJZUT. 13. Шавловская О.А., Бокова И.А., Шавловский Н.И. Мелоксикам в терапии болевого синдрома у пациентов с коморбидными заболеваниями. Медицинский совет. 2021; (19): 209–215. (Shavlovskaya O.A., Bokova I.A., Shavlovskiy N.I. Meloxicam in pain syndrome treatment of comorbid diseases patients. Meditsinskiy sovet = Medical Council. 2021; (19): 209–215 (In Russ.)). https://doi.org/10.21518/2079-701X-2021-19-209-215. EDN: RFZAZX. 14. Никифоров Р.В., Шевцова В.И., Зуйкова А.А. Оценка прогипертензивного влияния мелоксикама на показатели артериального давления. Архивъ внутренней медицины. 2019; 9(1): 60–63. (Nikiforov R.V., Shevtsova V.I., Zuykova A.A. Evaluation of prohypertensive effect of meloxicam on the blood pressure indicators. Arkhiv vnutrenney meditsiny = Archive of Internal Medicine. 2019; 9(1): 60–63 (In Russ.)). https://doi.org/10.20514/2226-6704-2019-9-1-60-63. EDN: YWHYOL. 15. Каратеев Д.Е., Лучихина Е.Л., Тангиева А.Р. Выбор нестероидного противовоспалительного препарата для симптоматической терапии ревматических заболеваний: фокус на Нимесулид. Эффективная фармакотерапия. 2018; (19): 26–31. (Karateev D.E., Luchikhina E.L., Tangieva A.R. Selection of non-steroidal anti-inflammatory drug for symptomatic therapy of rheumatic diseases: Focus on nimesulide. Effectivnaya farmakoterapiya = Effective Pharmacotherapy. 2018; (19): 26–31 (In Russ.)). EDN: XSMZQT. 16. Чупин А.В., Пизова Н.В., Коршунов Д.А. Пентоксифиллин при сосудистой патологии. РМЖ. 2023; (3): 15–20. (Chupin A.V., Pizova N.V., Korshunov D.A. Pentoxifylline in vascular pathology. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2023; (3): 15–20 (In Russ.)). EDN: WXOSNO. 17. D’Andrea E., Hey S.P., Ramirez C.L., Kesselheim A.S. Assessment of the role of niacin in managing cardiovascular disease outcomes: A systematic review and meta-analysis. JAMA Netw Open. 2019; 2(4): e192224. https://doi.org/10.1001/jamanetworkopen.2019.2224. PMID: 30977858. PMCID: PMC6481429.
About the Autors
Vasily S. Chulkov, MD, Dr. Sci. (Medicine), professor of the Department of internal diseases, Yaroslav-the-Wise Novgorod State University. Address: 173003, Veliky Novgorod, 41 Bolshaya Sankt-Petersburgskaya St.
E-mail: vschulkov@rambler.ru
ORCID: https://orcid.org/0000-0002-0952-6856
Tatyana I. Okonenko, MD, Dr. Sci. (Medicine), associate professor, head of the Department of general pathology, Yaroslav-the-Wise Novgorod State University. Address: 173003, Veliky Novgorod, 41 Bolshaya Sankt-Petersburgskaya St.
E-mail: Tatyana.Okonenko@novsu.ru
ORCID: https://orcid.org/0000-0002-7431-3777
Alexander K. Khrutsky, MD, assistant at the Department of pharmacy, Yaroslav-the-Wise Novgorod State University. Address: 173003, Veliky Novgorod, 41 Bolshaya Sankt-Petersburgskaya St.
E-mail: khrutsky@mail.ru
ORCID: https://orcid.org/0000-0001-5372-4350
Svetlana V. Zhmaylova, MD, Dr. Sci. (Medicine), head of the Department of additional professional training and outpatient therapy, Yaroslav-the-Wise Novgorod State University. Address: 173003, Veliky Novgorod, 41 Bolshaya Sankt-Petersburgskaya St.
E-mail: Svetlana.Zhmaylova@novsu.ru
ORCID: https://orcid.org/0000-0002-7754-5338
Similar Articles
